Who are BNT162b7 Monovalent (OMI BA.4/BA.5)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BNT162b2 (Omi XBB.1.5), mRNA-1273, BNT162b2 (2025/2026 formulation), BNT162b4 5 mcg, protein subunit: Novavax COVID-19 vaccine, CCP.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bnt162b7-monovalent-omi-ba-4-ba-5.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

BNT162b7 Monovalent (OMI BA.4/BA.5) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BNT162b7 Monovalent (OMI BA.4/BA.5) (bnt162b7-monovalent-omi-ba-4-ba-5) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

marketed vaccine SARS-CoV-2 spike protein Immunology Live · refreshed every 30 min

Target snapshot

BNT162b7 Monovalent (OMI BA.4/BA.5) (bnt162b7-monovalent-omi-ba-4-ba-5) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BNT162b7 Monovalent (OMI BA.4/BA.5) TARGET	bnt162b7-monovalent-omi-ba-4-ba-5	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
BNT162b2 (Omi XBB.1.5)	bnt162b2-omi-xbb-1-5	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
mRNA-1273	mRNA-1273	Assistance Publique - Hôpitaux de Paris	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
BNT162b2 (2025/2026 formulation)	bnt162b2-2025-2026-formulation	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
BNT162b4 5 mcg	bnt162b4-5-mcg	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
protein subunit: Novavax COVID-19 vaccine	protein subunit: Novavax COVID-19 vaccine	Novavax	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein
CCP	CCP	Metro Infectious Disease Consultants	marketed	Convalescent plasma	SARS-CoV-2 spike protein and other viral antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (vaccine class)

Pfizer · 20 drugs in this class
Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
GlaxoSmithKline · 12 drugs in this class
Merck Sharp & Dohme LLC · 12 drugs in this class
Centers for Disease Control and Prevention · 9 drugs in this class
Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
Beijing Center for Disease Control and Prevention · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BNT162b7 Monovalent (OMI BA.4/BA.5) — Competitive Intelligence Brief. https://druglandscape.com/ci/bnt162b7-monovalent-omi-ba-4-ba-5. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab